They found that the anti-VEGFR2 antibody treatment is associated with lymphocyte homing into the tumor, whereas the anti-PD-L1 antibody induces activation of infiltrated CD4+ and CD8+ T cells that produce IFNγ. The gene discussed is CD274; the disease is neoplasm.